Status:
UNKNOWN
The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology
Lead Sponsor:
Shandong University
Conditions:
Helicobacter Gastritis
Eligibility:
All Genders
18-70 years
Brief Summary
Subjects who are included will recieve Hp eradication therapy based on antimicrobial susceptibility test. After the therapy, the subjects will be divided into two groups, the successful group and the ...
Detailed Description
Subjects who are included will recieve Hp eradication therapy based on antimicrobial susceptibility test. After the therapy, the subjects will be divided into two groups, the successful group and the ...
Eligibility Criteria
Inclusion
- Patients, aged between 18 and 70 years old, with positive H. pylori infection that was not eradicated by previous therapies are included. The H. pylori infection is confirmed by the positive rapid urease test or 13C-breath test.
Exclusion
- Patients with significant underlying disease including liver, cardiac, pulmonary, and renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, patients with peptic ulcer, the use of PPI, NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of allergic reactions to any of the medications used in this protocol. Patients previously treated with H. pylori eradication regimens or those unwilling to participate in the study were also excluded.
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2021
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04029441
Start Date
September 1 2018
End Date
September 30 2021
Last Update
July 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hosipital
Jinan, Shandong, China, 250012